Treatments for colorectal liver metastases: a new focus on a familiar concept

Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of lif...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2016-12, Vol.108, p.154-163
Main Authors: Zampino, M.G, Magni, E, Ravenda, P.S, Cella, C.A, Bonomo, G, Della Vigna, P, Galdy, S, Spada, F, Varano, G.M, Mauri, G, Fazio, N, Orsi, F
Format: Article
Language:English
Subjects:
Ablative therapies
Chemoembolization, Therapeutic
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Disease-Free Survival
Hematology, Oncology and Palliative Medicine
Hepatectomy
Humans
Intra-arterial chemotherapy
Liver metastases
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Loco-regional therapies
Quality of Life
Radio-embolization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3
cites cdi_FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3
container_end_page 163
container_issue
container_start_page 154
container_title Critical reviews in oncology/hematology
container_volume 108
creator Zampino, M.G
Magni, E
Ravenda, P.S
Cella, C.A
Bonomo, G
Della Vigna, P
Galdy, S
Spada, F
Varano, G.M
Mauri, G
Fazio, N
Orsi, F
description Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of life. This paper debates the rationale and current liver-directed approaches for colorectal liver metastases based on the evidence of literature and new clinical trials. Surgery is the gold standard, when feasible, and it’s the main treatment goal for patients with potentially-resectable disease as a means of prolonging progression-free survival. Better tumor response rates with modern systemic therapy mean that more unresectable patients are now down-staged for radical resection following conversion therapy but for other patients, additional procedures are needed. In multiple unilobar disease, when the projected remnant liver is
doi_str_mv 10.1016/j.critrevonc.2016.11.005
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1847889318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1040842816303171</els_id><sourcerecordid>1847889318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0EomXhL6Ace0nwJE7s5VCpVOVDKuJAOVvOZCx568RbO9mq_74O24LECcmSZ6z3nfE8w1gBvAIO3YddhdHNkQ5hwqrOLxVAxXn7gp2CktuSiw5e5pgLXipRqxP2JqUd51yITr5mJ7XcNqAaccq-30Qy80jTnAobYoHBh0g4G194d6BYjDSblA-lj4UpJrrPMlxSEaacWjM678xqm5D281v2yhqf6N3TvWG_Pl_dXH4tr398-XZ5cV2iqLdzaWtoQbbCCAOyy59qjMIe7DDYTg1bkaMeem77ATtAqdpWou1rS0htT0PfbNjZse4-hruF0qxHl5C8NxOFJWlQQir1e8YNU0cpxpBSJKv30Y0mPmjgeoWpd_ovTL3C1AA6w8zW909dln6k4Y_xmV4WfDoKKM96cBR1QkeZxOBWhnoI7n-6nP9TBL2bHBp_Sw-UdmGJU2apQadac_1zXeq6U-ga3oCE5hGo6aFC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1847889318</pqid></control><display><type>article</type><title>Treatments for colorectal liver metastases: a new focus on a familiar concept</title><source>Elsevier</source><creator>Zampino, M.G ; Magni, E ; Ravenda, P.S ; Cella, C.A ; Bonomo, G ; Della Vigna, P ; Galdy, S ; Spada, F ; Varano, G.M ; Mauri, G ; Fazio, N ; Orsi, F</creator><creatorcontrib>Zampino, M.G ; Magni, E ; Ravenda, P.S ; Cella, C.A ; Bonomo, G ; Della Vigna, P ; Galdy, S ; Spada, F ; Varano, G.M ; Mauri, G ; Fazio, N ; Orsi, F</creatorcontrib><description>Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of life. This paper debates the rationale and current liver-directed approaches for colorectal liver metastases based on the evidence of literature and new clinical trials. Surgery is the gold standard, when feasible, and it’s the main treatment goal for patients with potentially-resectable disease as a means of prolonging progression-free survival. Better tumor response rates with modern systemic therapy mean that more unresectable patients are now down-staged for radical resection following conversion therapy but for other patients, additional procedures are needed. In multiple unilobar disease, when the projected remnant liver is &lt;30% of the total liver, portal embolization or selective-internal-radiation-therapy (SIRT) can induce hypertrophy of the healthy liver, leading to resectability. In multiple bilobar disease, in situ destruction of non-resectable lesions by minimally invasive techniques may be associated with liver resection to achieve potential curative intent. Other palliative liver-directed approaches, such as SIRT or intra-hepatic chemotherapy (HAI), which are associated with higher response rates, may also have role in down-staging patients for resection. Until recently, such technologies have not been validated in prospective controlled trials. However in the light of new Phase 3 data for SIRT as well as for HAI combined with modern therapies or radiofrequency ablation in the first- and second-line setting, the clinical value of these treatments needs to be re-appraised.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2016.11.005</identifier><identifier>PMID: 27931834</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Ablative therapies ; Chemoembolization, Therapeutic ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Disease-Free Survival ; Hematology, Oncology and Palliative Medicine ; Hepatectomy ; Humans ; Intra-arterial chemotherapy ; Liver metastases ; Liver Neoplasms - secondary ; Liver Neoplasms - therapy ; Loco-regional therapies ; Quality of Life ; Radio-embolization</subject><ispartof>Critical reviews in oncology/hematology, 2016-12, Vol.108, p.154-163</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3</citedby><cites>FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27931834$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zampino, M.G</creatorcontrib><creatorcontrib>Magni, E</creatorcontrib><creatorcontrib>Ravenda, P.S</creatorcontrib><creatorcontrib>Cella, C.A</creatorcontrib><creatorcontrib>Bonomo, G</creatorcontrib><creatorcontrib>Della Vigna, P</creatorcontrib><creatorcontrib>Galdy, S</creatorcontrib><creatorcontrib>Spada, F</creatorcontrib><creatorcontrib>Varano, G.M</creatorcontrib><creatorcontrib>Mauri, G</creatorcontrib><creatorcontrib>Fazio, N</creatorcontrib><creatorcontrib>Orsi, F</creatorcontrib><title>Treatments for colorectal liver metastases: a new focus on a familiar concept</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of life. This paper debates the rationale and current liver-directed approaches for colorectal liver metastases based on the evidence of literature and new clinical trials. Surgery is the gold standard, when feasible, and it’s the main treatment goal for patients with potentially-resectable disease as a means of prolonging progression-free survival. Better tumor response rates with modern systemic therapy mean that more unresectable patients are now down-staged for radical resection following conversion therapy but for other patients, additional procedures are needed. In multiple unilobar disease, when the projected remnant liver is &lt;30% of the total liver, portal embolization or selective-internal-radiation-therapy (SIRT) can induce hypertrophy of the healthy liver, leading to resectability. In multiple bilobar disease, in situ destruction of non-resectable lesions by minimally invasive techniques may be associated with liver resection to achieve potential curative intent. Other palliative liver-directed approaches, such as SIRT or intra-hepatic chemotherapy (HAI), which are associated with higher response rates, may also have role in down-staging patients for resection. Until recently, such technologies have not been validated in prospective controlled trials. However in the light of new Phase 3 data for SIRT as well as for HAI combined with modern therapies or radiofrequency ablation in the first- and second-line setting, the clinical value of these treatments needs to be re-appraised.</description><subject>Ablative therapies</subject><subject>Chemoembolization, Therapeutic</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Disease-Free Survival</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>Intra-arterial chemotherapy</subject><subject>Liver metastases</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - therapy</subject><subject>Loco-regional therapies</subject><subject>Quality of Life</subject><subject>Radio-embolization</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhi0EomXhL6Ace0nwJE7s5VCpVOVDKuJAOVvOZCx568RbO9mq_74O24LECcmSZ6z3nfE8w1gBvAIO3YddhdHNkQ5hwqrOLxVAxXn7gp2CktuSiw5e5pgLXipRqxP2JqUd51yITr5mJ7XcNqAaccq-30Qy80jTnAobYoHBh0g4G194d6BYjDSblA-lj4UpJrrPMlxSEaacWjM678xqm5D281v2yhqf6N3TvWG_Pl_dXH4tr398-XZ5cV2iqLdzaWtoQbbCCAOyy59qjMIe7DDYTg1bkaMeem77ATtAqdpWou1rS0htT0PfbNjZse4-hruF0qxHl5C8NxOFJWlQQir1e8YNU0cpxpBSJKv30Y0mPmjgeoWpd_ovTL3C1AA6w8zW909dln6k4Y_xmV4WfDoKKM96cBR1QkeZxOBWhnoI7n-6nP9TBL2bHBp_Sw-UdmGJU2apQadac_1zXeq6U-ga3oCE5hGo6aFC</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Zampino, M.G</creator><creator>Magni, E</creator><creator>Ravenda, P.S</creator><creator>Cella, C.A</creator><creator>Bonomo, G</creator><creator>Della Vigna, P</creator><creator>Galdy, S</creator><creator>Spada, F</creator><creator>Varano, G.M</creator><creator>Mauri, G</creator><creator>Fazio, N</creator><creator>Orsi, F</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Treatments for colorectal liver metastases: a new focus on a familiar concept</title><author>Zampino, M.G ; Magni, E ; Ravenda, P.S ; Cella, C.A ; Bonomo, G ; Della Vigna, P ; Galdy, S ; Spada, F ; Varano, G.M ; Mauri, G ; Fazio, N ; Orsi, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Ablative therapies</topic><topic>Chemoembolization, Therapeutic</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Disease-Free Survival</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>Intra-arterial chemotherapy</topic><topic>Liver metastases</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - therapy</topic><topic>Loco-regional therapies</topic><topic>Quality of Life</topic><topic>Radio-embolization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zampino, M.G</creatorcontrib><creatorcontrib>Magni, E</creatorcontrib><creatorcontrib>Ravenda, P.S</creatorcontrib><creatorcontrib>Cella, C.A</creatorcontrib><creatorcontrib>Bonomo, G</creatorcontrib><creatorcontrib>Della Vigna, P</creatorcontrib><creatorcontrib>Galdy, S</creatorcontrib><creatorcontrib>Spada, F</creatorcontrib><creatorcontrib>Varano, G.M</creatorcontrib><creatorcontrib>Mauri, G</creatorcontrib><creatorcontrib>Fazio, N</creatorcontrib><creatorcontrib>Orsi, F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zampino, M.G</au><au>Magni, E</au><au>Ravenda, P.S</au><au>Cella, C.A</au><au>Bonomo, G</au><au>Della Vigna, P</au><au>Galdy, S</au><au>Spada, F</au><au>Varano, G.M</au><au>Mauri, G</au><au>Fazio, N</au><au>Orsi, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatments for colorectal liver metastases: a new focus on a familiar concept</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>108</volume><spage>154</spage><epage>163</epage><pages>154-163</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Abstract A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of life. This paper debates the rationale and current liver-directed approaches for colorectal liver metastases based on the evidence of literature and new clinical trials. Surgery is the gold standard, when feasible, and it’s the main treatment goal for patients with potentially-resectable disease as a means of prolonging progression-free survival. Better tumor response rates with modern systemic therapy mean that more unresectable patients are now down-staged for radical resection following conversion therapy but for other patients, additional procedures are needed. In multiple unilobar disease, when the projected remnant liver is &lt;30% of the total liver, portal embolization or selective-internal-radiation-therapy (SIRT) can induce hypertrophy of the healthy liver, leading to resectability. In multiple bilobar disease, in situ destruction of non-resectable lesions by minimally invasive techniques may be associated with liver resection to achieve potential curative intent. Other palliative liver-directed approaches, such as SIRT or intra-hepatic chemotherapy (HAI), which are associated with higher response rates, may also have role in down-staging patients for resection. Until recently, such technologies have not been validated in prospective controlled trials. However in the light of new Phase 3 data for SIRT as well as for HAI combined with modern therapies or radiofrequency ablation in the first- and second-line setting, the clinical value of these treatments needs to be re-appraised.</abstract><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>27931834</pmid><doi>10.1016/j.critrevonc.2016.11.005</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1040-8428
ispartof Critical reviews in oncology/hematology, 2016-12, Vol.108, p.154-163
issn 1040-8428
1879-0461
language eng
recordid cdi_proquest_miscellaneous_1847889318
source Elsevier
subjects Ablative therapies
Chemoembolization, Therapeutic
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Disease-Free Survival
Hematology, Oncology and Palliative Medicine
Hepatectomy
Humans
Intra-arterial chemotherapy
Liver metastases
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Loco-regional therapies
Quality of Life
Radio-embolization
title Treatments for colorectal liver metastases: a new focus on a familiar concept
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatments%20for%20colorectal%20liver%20metastases:%20a%20new%20focus%20on%20a%20familiar%20concept&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Zampino,%20M.G&rft.date=2016-12-01&rft.volume=108&rft.spage=154&rft.epage=163&rft.pages=154-163&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2016.11.005&rft_dat=%3Cproquest_cross%3E1847889318%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-f2151754a4a1760443a8cb1fddf68d941fdb1b0fbdc61c78557cfb2fece5bedb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1847889318&rft_id=info:pmid/27931834&rfr_iscdi=true